ADmit Therapeutics
Biotechnology-Research
Website
Company Tagline
Identification of an early Alzheimer's disease will accelerate the identification of curative drugs
Industry Category
Business Keywords
Company Description
ADmit Therapeutics is a leading biotechnology company dedicated to the commercialization of innovative diagnostic solutions. Focused on improving patient outcomes through early and accurate disease prognosis, ADmit Therapeutics is committed to advancing the field of personalized medicine.
With a primary focus on the MAP-AD Test, an epigenetic IVD Test designed for the prognosis of Alzheimer’s disease, ADmit Therapeutics is at the forefront of dementia research and diagnostics. Located at Crta. Laureà Miró, 408-410, Sant Feliu de Llobregat, Barcelona 08980, ES, ADmit Therapeutics leverages cutting-edge epigenetics and next-generation sequencing technologies to provide impactful healthcare solutions.
ADmit Therapeutics strives to make significant contributions to the understanding and management of Alzheimer's disease. The company's ongoing efforts promise a future where early diagnosis leads to more effective treatment strategies. ADmit Therapeutics welcomes you to explore opportunities for collaboration and partnership. Manager, we invite you to create a customized and exclusive company showcase and product listing on our platform.
ADmit Therapeutics es una empresa biotecnológica líder dedicada a la comercialización de soluciones de diagnóstico innovadoras. Centrada en mejorar los resultados de los pacientes a través del pronóstico temprano y preciso de enfermedades, ADmit Therapeutics está comprometida con el avance del campo de la medicina personalizada.
Con un enfoque principal en la prueba MAP-AD, una prueba IVD epigenética diseñada para el pronóstico de la enfermedad de Alzheimer, ADmit Therapeutics está a la vanguardia de la investigación y el diagnóstico de la demencia. Ubicada en Crta. Laureà Miró, 408-410, Sant Feliu de Llobregat, Barcelona 08980, ES, ADmit Therapeutics aprovecha la epigenética de vanguardia y las tecnologías de secuenciación de próxima generación para proporcionar soluciones de atención médica impactantes.
ADmit Therapeutics se esfuerza por realizar contribuciones significativas a la comprensión y el manejo de la enfermedad de Alzheimer. Los esfuerzos continuos de la compañía prometen un futuro donde el diagnóstico temprano conduzca a estrategias de tratamiento más efectivas. ADmit Therapeutics le invita a explorar oportunidades de colaboración y asociación. Gerente, lo invitamos a crear una presentación de empresa y una lista de productos personalizadas y exclusivas en nuestra plataforma.
Key Personnel / Employees
Compare Companies Side by Side
Compare ADmit Therapeutics with 3 companies in Biotechnology-Research
| Comparison Field |
ADmit TherapeuticsMain Company |
Alzheimer EuropeView Profile |
Mentia HealthView Profile |
Cancer Research and...View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 1990 | 2017 | 2019 |
|
Company Size
|
— | 11-50 | 11-50 | 2-10 |
|
City
|
Sant Feliu de Llobregat, Barcelona | San Francisco, California | Baar, Zug | |
|
Country
|
Spain | United States | Switzerland | |
|
Skills & Keywords
Comparing with main company
|
9 Total Skills
Biotechnology
Epigenetics
Alzheimer's Disease
IVD Test
Next Generation Sequencing
Dementia Research
Personalized Medicine
Dementia
Alzheimer's disease
|
6 Total
6 Unique
Unique Skills:
Ethical issues
EU collaboration
EU projects
H2020
Human rights
Research
|
12 Total
12 Unique
Unique Skills:
aging-in-place
behavioral health
Creative therapeutics
Digital health
Family caregiving
home health
+6
|
25 Total
25 Unique
Unique Skills:
Altzheimer's
Apoptosis
Breast cancer
Cancer
Cancer prevention
Carcinogens
+19
|
4
Total Companies1990
Oldest Founded3
Countries51
Unique SkillsSimilar Companies
Other organizations in the same industry
Bioheng Therapeutics
Biotechnology-ResearchWe are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T
Differentia Bio
Biotechnology-ResearchKnowledge-empowered modeling and simulation for effective drug development
Algorae Pharmaceuticals (ASX: 1AI)
Biotechnology-ResearchAI enhanced drug discovery and development (ASX: 1AI)
Riva Therapeutics
Biotechnology-ResearchCharting the Course to a New Generation of Oncology Precision Medicines
Alternative Company Names
This company is also known as